Supernus Pharmaceuticals Earnings Call Signals Growth Momentum

Supernus Pharmaceuticals ((SUPN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Supernus Pharmaceuticals’ latest earnings call struck an overall optimistic tone, with management highlighting powerful revenue growth, stronger non‑GAAP profitability, and a debt‑free balance sheet. While executives acknowledged rising operating costs, lingering GAAP losses, and supply risks around Onepco, they argued that the company’s expanding product portfolio and advancing pipeline position it well for long‑term value creation.

Broad-Based Revenue Acceleration

Supernus reported Q1 2026 total revenue of $207.7 million, a 39% jump from a year earlier, underscoring strong demand across its portfolio. Growth products were the standout, with combined revenues up 56% year over year, while commercial product sales reached $178 million, rising 26% versus the prior‑year quarter.

Profitability Trends: Better Non-GAAP, Narrower GAAP Loss

Non‑GAAP adjusted operating earnings climbed to $28.7 million from $25.9 million, an 11% improvement that points to better underlying profitability. On a GAAP basis, the company still posted a loss, but it narrowed meaningfully to $2.3 million, or $0.04 per share, compared with an $11.8 million loss, or $0.21 per share, a year ago.

Onepco Shows Signs of Commercial Rebound

Onepco generated $8.4 million in net sales in Q1, reflecting only a partial benefit from new patient initiations that resumed in February 2026 after supply disruptions. March prescriptions climbed to 463, surpassing October 2025 levels, and the month also delivered the highest number of prescribers with shipments since launch, suggesting a rebuilding commercial trajectory.

XERJUVEY and Partnered Franchise Momentum

Collaboration revenues totaled $27.6 million in the quarter, helped by sharp growth in partnered product XERJUVEY. Biogen reported U.S. XERJUVEY sales roughly doubled year over year, with around 29,000 patients treated since launch and about 85% of prescriptions coming from routine prescribers, indicating broad and deepening physician adoption.

KELLI (CalRit) Outpaces ADHD Market Growth

KELLI continued to outperform the broader ADHD category, with prescriptions up 19% versus a 10% market expansion, according to IQVIA. Net sales reached $78 million, up 20% year over year, driven by a 27% gain in adult new prescriptions, 15% growth in pediatric scripts, and a prescriber base of about 43,000, where adult prescribers now exceed pediatric for the first time.

GOCOVRI Delivers Steady Expansion

GOCOVRI posted net sales of $35.2 million in Q1 2026, a 15% increase compared with the same period in 2025, demonstrating steady uptake in its niche. Total prescriptions rose 7% year over year, highlighting continued penetration among patients and prescribers despite a competitive neurology landscape.

Cash-Rich, Debt-Free Balance Sheet

The company ended March 31, 2026 with approximately $384 million in cash, cash equivalents and marketable securities, and reported no debt, giving it ample flexibility to fund growth. Q1 results also included $29.3 million in royalty, licensing and other revenues, bolstered by a $20 million licensing milestone from Shinobi, adding to financial firepower.

Advancing R&D Pipeline

Supernus emphasized progress across multiple clinical programs, underscoring its push beyond current commercial assets. Key efforts include SPN‑820 in a Phase 2b trial for major depressive disorder, SPN‑817 in a Phase 2b study for treatment‑resistant focal seizures, and the planned initiation of a Phase 1 trial for SPN‑443 in 2026, supporting a diversified future product lineup.

Operating Expense Surge Weighs on Margins

Operating costs rose sharply, with combined R&D and SG&A expenses reaching $164.6 million, up from $116.9 million a year earlier, a roughly 41% increase. Management attributed much of the jump to higher SG&A tied to the Biogen collaboration and signaled that spending will remain elevated, with full‑year combined R&D and SG&A expected between $620 million and $650 million.

Onepco Supply Constraints and Conversion Challenges

Despite the rebound, Onepco remains constrained by supply and process bottlenecks, with the company estimating that 40%–45% of patients drop off between enrollment form and shipment. A backlog of about 570 patients, down from roughly 700, still needs to be converted, and management cautioned that Q1 improvements largely reflected March activity, leaving full recovery dependent on further processing gains and steady supply.

Second-Supplier Dependence and Regulatory Timing Risk

To reduce supply risk, Supernus plans to submit its second supplier for regulatory review in the third quarter of 2026, with potential approval by mid‑2027 assuming a six‑ to nine‑month review. Management stressed that the timeline ultimately depends on U.S. regulators’ review and inspections, leaving the company exposed to potential delays before full redundancy is secured.

GAAP Losses and Wide Earnings Guidance Range

The quarter still produced a GAAP operating loss of $8.3 million, albeit better than the $10.3 million loss a year earlier, highlighting that profitability is not yet firmly established on a GAAP basis. Full‑year GAAP operating earnings guidance of $0 to $30 million is notably wide, reflecting ongoing uncertainty around execution, costs and timing of key initiatives.

GAAP vs. Non-GAAP Gap Highlights Volatility

Guidance underscores a substantial gap between GAAP and non‑GAAP expectations, with non‑GAAP operating earnings forecast at $140 million to $170 million versus just $0 to $30 million on a GAAP basis. This implies sizable reconciling items and suggests that investors should brace for potential volatility between reported GAAP results and adjusted performance metrics.

Early-Stage Uncertainty in Persistence Metrics

Management cautioned that persistence and refill behavior for Onepco and other recently restarted programs remain in early stages and are not yet well characterized. The company flagged titration‑related dropouts and limited real‑world data, meaning long‑term adherence and revenue durability still carry meaningful uncertainty.

Guidance and Outlook Emphasize Growth with Caution

Supernus reaffirmed 2026 guidance for total revenues between $840 million and $870 million and combined R&D and SG&A of $620 million to $650 million, targeting GAAP operating earnings of $0 to $30 million and non‑GAAP operating earnings of $140 million to $170 million. The company also highlighted an expected regulatory filing for a second Onapro supplier in Q3 2026, potential approval before mid‑2027, plans to start a Phase 1 study for SPN‑443 in 2026, and the strength of its $384 million cash position with no debt.

Supernus’ earnings call painted a picture of a company in transition, leveraging strong top‑line growth and a healthy balance sheet while navigating higher costs, supply hurdles and evolving persistence trends. For investors, the story blends clear momentum in core and partnered products with execution and regulatory risks, suggesting that future quarters will test management’s ability to translate today’s growth into durable, GAAP‑level profitability.